SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Net Asset Value(s)

13 Mar 2020 07:00

RNS Number : 0228G
RTW Venture Fund Limited
13 March 2020
 

LEI: 549300Q7EXQQH6KF7Z84

13 March 2020

RTW Venture Fund Limited

Net Asset Value

RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value of the Company at the close of business on 28 February 2020 (the "NAV") was US$207.57 million, or US$1.20 per ordinary share.

As at 28 February 2020, 13.5 per cent. of the NAV was invested cent in privately-held companies.

For Further Information

RTW Investments, LP

Stephanie Sirota, Chief Business OfficerAlexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

 

Estera (Company Secretary)

Kevin Smith

 

+1 (646) 343 9280

 

 

 

+44 (0) 1481 742 642

 

J.P. Morgan Cazenove

William Simmonds

Oliver Kenyon

James Bouverat (Sales)

 

Barclays

Tom Swerling

Andrew Tusa

Ryan McCarthy

+44 (0)20 7742 4000

 

 

 

+44 (0)20 7623 2323

 

Note:

1.

The NAV is determined by the Company's investment manager, RTW Investments, LP, in accordance with the Company's accounting policies. Investments by the Company in privately-held companies ("Private Portfolio Companies") have been valued at fair market value, taking into account the valuation prepared by Alvarez & Marsal Valuation Services LLC as at 28 February 2020 and the nature, facts and circumstances of the Private Portfolio Companies since that date. Investments by the Company in companies listed on a public stock exchange (the "Public Portfolio Companies") have each been valued by reference to their market capitalisation as at close of business on 28 February 2020. The Company applies a valuation discount to its investments in Public Portfolio Companies that are subject to post-IPO lock-up provisions.

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NAVGPUBPWUPUUUW
Date   Source Headline
19th Aug 20217:05 amRNSDirector/PDMR Shareholding
19th Aug 20217:05 amRNSDirector/PDMR Shareholding
19th Aug 20217:00 amRNSNotice of Interim Report
17th Aug 20217:00 amRNSIssue of Equity
13th Aug 20214:05 pmRNSAnnouncement of Share Issuance
13th Aug 20217:00 amRNSNet Asset Value(s)
6th Aug 20217:00 amRNSCompletion of Transfer
5th Aug 20211:00 pmRNSTransfer to the Premium Segment of the LSE
2nd Aug 20217:01 amRNSPortfolio Company Update: Tenaya Therapeutics IPO
2nd Aug 20217:00 amRNSQuarterly Update
30th Jul 20213:50 pmRNSResult of Meeting
27th Jul 20217:05 amRNSNew Investment in Artios
15th Jul 20217:00 amRNSNet Asset Value(s)
14th Jul 20217:05 amRNSPortfolio Company Update
14th Jul 20217:00 amRNSPublication of Circular
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 20217:00 amRNSPortfolio Company Update: GH Research IPO
25th Jun 20217:00 amRNSPortfolio Company Update: Monte Rosa IPO
22nd Jun 20214:49 pmRNSResult of AGM
18th Jun 20214:40 pmRNSSecond Price Monitoring Extn
18th Jun 20214:35 pmRNSPrice Monitoring Extension
16th Jun 20217:00 amRNSIssue of Equity
15th Jun 202112:05 pmRNSNew Investment in Umoja Biopharma
14th Jun 20212:32 pmRNSAnnouncement of Share Issuance
14th Jun 20217:00 amRNSNet Asset Value(s)
9th Jun 202112:05 pmRNSNew Investment in Alcyone Therapeutics
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20211:05 pmRNSAdditional Investment in Portfolio Company
20th May 20218:05 amRNSNew Investment in Numab Therapeutics
14th May 20217:00 amRNSNet Asset Value(s)
29th Apr 20217:00 amRNSAnnual Financial Report
28th Apr 20217:00 amRNSQuarterly Update
19th Apr 20217:00 amRNSPortfolio Company Update: Biomea IPO
15th Apr 20217:00 amRNSNet Asset Value(s)
1st Apr 20217:05 amRNSTotal Voting Rights
1st Apr 20217:00 amRNSNotice of Annual Report
30th Mar 20211:00 pmRNSNew Investment in Pyxis Oncology
17th Mar 20217:00 amRNSIssue of Equity
15th Mar 20217:01 amRNSAnnouncement of Share Issuance
15th Mar 20217:00 amRNSPortfolio Company Update: Prometheus IPO
12th Mar 202112:30 pmRNSNew Investment in Monte Rosa Therapeutics
12th Mar 20217:00 amRNSNet Asset Value(s)
9th Mar 20211:45 pmRNSNew Investment in Ventyx Biosciences
9th Mar 202112:45 pmRNSNew Investment in Visus Therapeutics
1st Mar 20211:00 pmRNSNew Investment in Tenaya Therapeutics
1st Mar 20217:00 amRNSTotal Voting Rights
26th Feb 20211:15 pmRNSNew Investment in Artiva Biotherapeutics
18th Feb 20217:00 amRNSIssue of Equity
15th Feb 20214:10 pmRNSAnnouncement of Share Issuance
15th Feb 20217:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.